ArticleJournal of clinical medicine2022
Ocular Inflammation Induced by Immune Checkpoint Inhibitors.
Article in Journal of clinical medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 37 citations in OpenAlex.
- Ocular toxicities associated with anticancer drug therapy in Asian patients: a literature review and practical management recommendations for non-ophthalmologic settings.International journal of clinical oncology · 2026Review
- Acral lentiginous melanoma metastases to the vitreous masquerading as uveitis: A case report.American journal of ophthalmology case reports · 2026Article
- Immune Checkpoint Inhibitor-Induced Vogt-Koyanagi-Harada-like Disease Complicated by Inflammatory Macular Neovascularisation: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Clinical features and prognosis of immune checkpoint inhibitor-associated ocular inflammation in Japanese patients: a case series.Japanese journal of ophthalmology · 2026Observational
- Rates of Drug-Induced Uveitis: A Review by Medication Class.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Case Report: Neuroretinitis following combination checkpoint inhibition therapy with nivolumab and ipilimumab for stage IIIC melanoma.Frontiers in oncology · 2026Article
- Update on Therapy for Non-Infectious Scleritis.Clinical ophthalmology (Auckland, N.Z.) · 2026Review
- Article
- Vogt-Koyanagi-Harada-like disease secondary to anticancer treatment: a multicentre case series.Eye (London, England) · 2025Article
- Immune checkpoint inhibitor-associated Vogt-Koyanagi-Harada-like syndrome: A descriptive systematic review.Journal of ophthalmic inflammation and infection · 2025Article
- Ocular toxicities of targeted therapies and immunotherapies in hematologic malignancies.Frontiers in oncology · 2025Review
- Ophthalmic Immune-Related Adverse Events and Association with Survival: Results From a Real-World Database.American journal of ophthalmology · 2024Article
- Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review.Biomedicines · 2024Review
- Clinical characteristics, treatment, and outcomes of pembrolizumab-induced uveitis.Investigational new drugs · 2024Article
- Cytokines in PD-1 immune checkpoint inhibitor adverse events and implications for the treatment of uveitis.BMC ophthalmology · 2024Review
- [Vasculitis of the retina : Clinical aspects, diagnostics, management and treatment].Die Ophthalmologie · 2024Review
- Nivolumab-associated immune-related filamentary keratitis.BMJ case reports · 2024Article
- Diagnosing and Managing Uveitis Associated with Immune Checkpoint Inhibitors: A Review.Diagnostics (Basel, Switzerland) · 2024Review
- Posterior-scleritis: Case report of an uncommon immune-related adverse event in the treatment of advanced endometrial cancer.Gynecologic oncology reports · 2023Article
- Ipilimumab-related uveitis and refractory hypotony with a flat chamber in a trabeculectomized eye with exfoliation glaucoma: A case report.American journal of ophthalmology case reports · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 13 institutions in 1 country.
Funding
Abstract
Ocular immunotherapy-related adverse events (IRAEs), although rare, can be sight-threatening. Our objective was to analyze ocular IRAEs diagnosed in France from the marketing of immune checkpoint inhibitors (ICPIs) until June 2021 and to review the literature. We collected the cases of 28 patients (36 ocular IRAEs), occurring after an average of 17 weeks (±19). Forty-six percent of patients were treated for metastatic melanoma. Anti-PD1 agents were responsible for 57% of the IRAEs. Anterior uveitis was the most common (44%), followed by panuveitis (28%). Of 25 uveitis cases, 80% were bilateral and 60% were granulomatous. We found one case with complete Vogt-Koyanagi-Harada syndrome and one case of birdshot retinochoroidopathy. The other IRAEs were eight ocular surface disorders, one optic neuropathy, and one inflammatory orbitopathy. Seventy percent of the IRAEs were grade 3 according to the common terminology of AEs. ICPIs were discontinued in 60% of patients and 50% received local corticosteroids alone. The literature review included 230 uveitis cases, of which 7% were granulomatous. The distributions of ICPIs, cancer, and type of uveitis were similar to our cohort. Ocular IRAEs appeared to be easily controlled by local or systemic corticosteroids and did not require routine discontinuation of ICPIs. Further work is still warranted to define the optimal management of ocular IRAEs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.